Focused On-demand Library for Heterogeneous nuclear ribonucleoproteins A2/B1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P22626

UPID:

ROA2_HUMAN

Alternative names:

Alternative UPACC:

P22626; A0A024RA27; A0A024RA61; A8K064; P22627; Q9UC98; Q9UDJ2

Background:

Heterogeneous nuclear ribonucleoproteins A2/B1 play a pivotal role in cellular processes, including mRNA processing, transport, and the stabilization of mature mRNAs. They form hnRNP particles, crucial for minimizing RNA tangling and ensuring efficient transcription and splicing. Additionally, these proteins are involved in the transport of specific mRNAs to the cytoplasm in neurons and oligodendrocytes, and play a role in innate immune response activation.

Therapeutic significance:

Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 2 is linked to variants affecting this protein. Understanding its role could lead to targeted therapies for this complex condition, highlighting its therapeutic significance.